The subsequent KATE3, randomized phase III trial is comparing T-DM1 in combination with atezolizumab vs. T-DM1 alone in patients with previously treated HER2-positive and PD-L1-positive metastatic BC (NCT04740918)[93]. This evidence concerns the gene ERBB2 and breast cancer.